Clinical Trial


An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)


Brief description

This study will investigate the efficacy, safety and tolerability of a new formulation of glatiramer acetate administered at 20 mg/0.5 ml daily versus placebo in patients with Relapsing-Remitting Multiple Sclerosis (RRMS).

Detailed Description

Approximately 1400 participants were planned for this study, however only 178 were enrolled prior to early termination.

Keywords

  •   Relapsing-Remitting Multiple Sclerosis

Sponsored By

Teva Pharmaceutical Industries

Unique Study ID

NCT01578785

Investigators and Research Sites Near You - Found( 3 )

No Investigator Listed

Dompé Farmaceutici S.p.A
48102, Tbilisi, Georgia
Distance from Current Trial is 0 miles

No Investigator Listed

Dompé Farmaceutici S.p.A
48159, Tbilisi, Georgia
Distance from Current Trial is 0 miles

No Investigator Listed

Dompé Farmaceutici S.p.A
48159, Tbilisi, Georgia
Distance from Current Trial is 0 miles
View All